Introduction
When injured, bone tissue has an outstanding ability to regenerate into native tissue. To guarantee the effective healing of native tissue, the fracture repair process needs either mechanical stability or a healthy biological environment, or both. Biologic adjuvants that can improve the biological environment and accelerate bone healing have been developed as a result of advances in our knowledge of the molecular and cellular processes involved in bone remodeling and repair. OrthoBiologics, such as stem cells, osteo-inductive growth factors, osteoconductive matrices, and anabolic agents, can be used in therapeutic settings to speed up the healing of fractures and treat conditions where bone healing is hindered, such as delayed unions and nonunion.
What Are the Biologic Adjuvants?
-
Although bone healing is not the only objective of fracture surgery, it is almost always the most difficult.
-
Osteogenic cells, osteo-inductive factors, and an osteoconductive scaffold are the three fundamental biologic prerequisites for reaching this objective of functional bone repair.
-
The mechanical environment is a crucial fourth element for success in the context of fractures, bone deformities, and nonunion.
-
The mechanical aspect of bone healing mustn't be overlooked in this conversation about the use of biologics because, without consideration of the mechanical aspect, functional bone repair cannot be achieved, and all related expenditures, time, and effort are squandered.
-
The term "biologics," as used by the United States Food and Drug Administration (FDA) covers a broad variety of goods, including blood and blood components, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins.
What Are the Types of Biologic Adjuvants?
Autologous Bone Grafts:
Because of their osteogenic, osteo-inductive, and osteoconductive qualities, autologous bone grafts continue to be the gold standard for improving bone repair. A tricortical iliac crest transplant is one form of bone autograft that can help with mechanical stability. Autologous bone transplants are also widely accessible and reasonably priced. Although bone harvesting can result in donor site morbidity, autograft eliminates the risk of inducing an immune response and disease transmission. However, there are drawbacks to taking bone from patients, such as chronic pain, infection, iatrogenic fractures, nerve damage, and, in some cases, a limited supply.
Platelet-Rich Plasma and Mesenchymal Stem Cells:
Mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP), two autogenous biologic treatments, are utilized largely for fracture nonunion to promote bone repair. By providing stimulation for fracture healing and reducing expenses, problems, and morbidity, these treatments aim to promote fracture union. MSCs are osteogenic, whereas PRP is osteo-inductive. PRP has been utilized to treat fractures due to its capacity to attract stem cells and endothelial cells. It is often used to treat soft tissue or articular pathologies.
Aspirate of Bone Marrow Concentrated:
The iliac crest bone graft (ICBG), which has been utilized for many years, is a natural extension of the bone marrow aspirate concentrate (BMAC), which was first reported in 1952. Only a small portion of mesenchymal stem cells (MSCs) can be extracted from the bone marrow through aspiration. Previously, these cells would have been multiplied through laboratory culture; however, a more recent motivation was to combine the harvest and implantation into a single surgical procedure. Aspiration from the posterior iliac crest is currently the norm, as it may be psychologically less distressing and is simple to reach with the needle.
Growth Factor Produced From Platelets:
The musculoskeletal system's PDGF regulates several cellular responses that are essential for tissue healing. Chemotaxis, the recruitment of mesenchymal stem cells (MSCs), angiogenesis, and the overexpression of vascular endothelial growth factors are a few examples. It is significant to note that PDGF initiates the native bone-healing cascade at the implant site. It was researched as an adjuvant therapy for complicated nonunion fractures as a result of these effects. It is significant to note that PDGF initiates the native bone-healing cascade at the implant site. It was researched as an adjuvant therapy for complicated nonunion fractures as a result of these effects.
Matrix of Demineralized Bone:
The biologic adjuvant demineralized bone matrix (DBM), which contains BMPs, collagen, and other growth factors and is subsequently mixed with a carrier, is made by demineralizing ground cadaver bone. Similar to PRP, every step of the manufacture of DBM, from harvesting to the finished product, is distinct from business to business, and there are no industry-wide standards.
Bone Morphogenic Proteins (BMPs):
As BMPs are created and promoted, their use has drastically expanded over the past few years. BMPs are a group of several distinct proteins found in the body, but only BMP-2 and BMP-7 have been permitted to be used in people. These have a very high risk of nonunion secondary to several variables, including the intensity of the trauma and potential infection, and they can be notoriously difficult to heal. But when BMP was added to the bone graft at the site, the authors of the BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) experiment discovered faster fracture healing and, more crucially, a lower rate of secondary intervention, such as the requirement for reoperation.
Autograft Vascularized:
Vascularized bone can be utilized to increase the likelihood of functional bone healing in some situations of stubborn nonunion, bone defect, or inadequate vascular bed (such as femoral head avascular necrosis). Cortico-cancellous bone graft is swiftly assimilated and biomechanically superior to non-vascularized autograft over the first 6 to 12 months, which is the period required for non-vascularized grafts to be incorporated. This is because the graft is transferred with its blood supply.
Applying Biologics to Implants:
Biologic materials are being looked into as a coating material for orthopedic implants, as well as fracture repair and fusion procedures. Despite being an essential part of orthopedic surgery, implants include several hazards that come with putting a foreign object into the body, such as infection, immunological response, inflammatory conditions, and non-integration. Implant coating is justified to lower these dangers.
Conclusion
Currently, a variety of biologic adjuvants are used in orthopedic surgery to treat a wide range of bone diseases. Research is actively looking for methods to improve and streamline widely utilized medicines while also examining potentially useful novel compounds. These developments, together with innovations in related areas like materials science, tissue engineering, and surgical technique, guarantee the field's ongoing dynamic expansion and advancement.
